Season 1 · Episode 18
S1 Ep18: FDA Approval Insights: Ponatinib in Ph+ ALL
OncLive® On Air · OncLive® On Air
April 8, 20249m 19s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr Jabbour expands on the multiple milestones achieved through ponatinib’s FDA approval for patients with Ph-positive ALL; the agent’s potency and unique mechanism of action; and key efficacy and safety data from the PhALLCON trial supporting this regulatory decision.